Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
InMed Pharmaceuticals (NASDAQ: INM) announced the immediate appointment of John Bathery to its Board of Directors, effective October 16, 2025.
Bathery brings more than 30 years of pharmaceutical experience, including 15+ years in corporate development, and has led transactions exceeding $60 billion. The company said his expertise will support advancement of INM-901 for Alzheimer’s and INM-089 for age-related macular degeneration toward clinical readiness and partnership exploration.
The release also said Bryan Baldasare will not stand for re-election at the December 18, 2025 annual meeting.
InMed Pharmaceuticals (NASDAQ: INM) ha annunciato l'immediata nomina di John Bathery al Consiglio di Amministrazione, con effetto dal 16 ottobre 2025.
Bathery porta con sé oltre 30 anni di esperienza nel settore farmaceutico, tra cui oltre 15 anni nel corporate development, e ha guidato transazioni per oltre $60 miliardi. L'azienda ha detto che la sua competenza sosterrà l'avanzamento di INM-901 per l'Alzheimer e di INM-089 per la degenerazione maculare correlata all'età verso la prontezza clinica e l'esplorazione di partnership.
Il comunicato ha anche affermato che Bryan Baldasare non si ripresenterà per la rielezione all'assemblea annuale del 18 dicembre 2025.
InMed Pharmaceuticals (NASDAQ: INM) anunció el nombramiento inmediato de John Bathery como miembro de su Junta Directiva, con efecto a partir del 16 de octubre de 2025.
Bathery aporta más de 30 años de experiencia farmacéutica, incluyendo más de 15 años en desarrollo corporativo, y ha liderado transacciones por más de $60 mil millones. La compañía indicó que su experiencia apoyará el avance de INM-901 para el Alzheimer y de INM-089 para la degeneración macular asociada a la edad hacia la preparación clínica y la exploración de asociaciones.
El comunicado también dijo que Bryan Baldasare no se presentará a la reelección en la asamblea anual del 18 de diciembre de 2025.
InMed Pharmaceuticals (NASDAQ: INM)는 2025년 10월 16일부로 이사회에 John Bathery를 즉시 임명했다고 발표했다.
Bathery는 제약 분야에서 30년 넘는 경력을 보유하고 있으며, 그 중 15년 이상은 기업개발에 종사했고 60억 달러 이상의 거래를 주도한 바 있다. 회사는 그의 전문성이 INM-901를 알츠하이머에, INM-089를 연령 관련 황반변성의 임상 준비와 파트너십 탐색을 가속하는 데 기여할 것이라고 밝혔다.
또한 발표에는 Bryan Baldasare가 2025년 12월 18일의 연례 주주총회에서 재선에 입후보하지 않을 것이라고 적혀 있다.
InMed Pharmaceuticals (NASDAQ: INM) a annoncé la nomination immédiate de John Bathery au conseil d'administration, à effet au 16 octobre 2025.
Bathery apporte plus de 30 ans d'expérience pharmaceutique, dont plus de 15 ans dans le développement d'entreprise, et a dirigé des transactions dépassant 60 milliards de dollars. L'entreprise a déclaré que son expertise soutiendra l'avancement de INM-901 pour l'Alzheimer et de INM-089 pour la dégénérescence maculaire liée à l'âge vers la préparation clinique et l'exploration de partenariats.
Le communiqué précise également que Bryan Baldasare ne se présentera pas à la réélection lors de l'assemblée annuelle du 18 décembre 2025.
InMed Pharmaceuticals (NASDAQ: INM) gab die sofortige Benennung von John Bathery in den Vorstand bekannt, wirksam ab dem 16. Oktober 2025.
Bathery bringt mehr als 30 Jahre Erfahrungen in der Pharmaindustrie mit, darunter über 15 Jahre im Bereich Corporate Development, und hat Transaktionen im Wert von über 60 Milliarden US-Dollar geleitet. Das Unternehmen sagte, seine Expertise werde die Weiterentwicklung von INM-901 für Alzheimer und INM-089 für altersbedingte Makuladegeneration in Richtung klinische Bereitschaft und Partnerschaftsersuche unterstützen.
In der Mitteilung hieß es auch, dass Bryan Baldasare bei der ordentlichen Hauptversammlung am 18. Dezember 2025 nicht erneut kandidieren wird.
InMed Pharmaceuticals (NASDAQ: INM) أعلنت تعيين جون باثيري فورا في مجلس إدارتها، اعتبارا من 16 أكتوبر 2025.
يجلب Bathery أكثر من 30 عاماً من الخبرة في صناعة الأدوية، بما في ذلك أكثر من 15 عاماً في التطوير المؤسسي، وقاد صفقات تفوق قيمتها 60 مليار دولار. وقالت الشركة إن خبرته ستدعم تقدم INM-901 لمرض الزهايمر وINM-089 لاضطراب التطور البقعي المرتبط بالعمر نحو الاستعداد السريري واستكشاف الشراكات.
كما ورد في البيان أن برايان بالداساري لن يترشح لإعادة انتخابه في اجتماع الجمعية العمومية السنوي في 18 ديسمبر 2025.
InMed Pharmaceuticals (NASDAQ: INM)宣布立即任命John Bathery加入董事会，生效日期为2025年10月16日。
Bathery 拥有超过30年的制药经验，其中15年在公司发展领域，并主导了超过600亿美元的交易。公司表示他的专业知识将支持< b>INM-901用于阿尔茨海默病、INM-089用于与年龄相关的黄斑变性临床就绪和伙伴关系探索。
公告还称Bryan Baldasare将不会在< b>2025年12月18日的年度股东大会上寻求连任。
- Appointed board member with 30+ years pharma experience
- Board addition brings deal experience across >$60B in transactions
- Audit Chair Bryan Baldasare will not stand for re-election on Dec 18, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately.
Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 years in corporate development and strategic partnerships. He currently serves as Head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals, where he has overseen pipeline and commercial divestitures, global alliance management, and integration of corporate transactions. Over his career, he has led and closed transactions with financial terms exceeding
Mr. Bathery's extensive background in evaluating preclinical and early-stage assets, structuring value-creating partnerships, and leading cross-functional global initiatives will be highly relevant as InMed advances both its INM-901 program for Alzheimer's disease and INM-089 program in Age-related Macular Degeneration ("AMD") toward clinical readiness and explores potential partnerships.
John Bathery commented:
"I am pleased to join InMed's Board at this pivotal stage in the Company's growth. The consistent positive results seen with INM-901 across multiple parameters are particularly encouraging and highlight the strength of InMed's research. I look forward to supporting the team as we advance InMed's programs and explore strategic opportunities to maximize their potential."
Additionally, the Company announced today that, due to increasing professional obligations, Mr. Bryan Baldasare has decided to not stand for re-election at the Company's December 18, 2025 Annual General Meeting.
Andrew Hull, Chairman of the Board of InMed, commented:
"We are delighted to welcome John to InMed's Board. His extensive deal-making expertise and proven ability to structure partnerships at the preclinical stage will be instrumental as we advance our development programs and pursue strategic collaborations. John's experience in global business development and corporate development will be a strong asset as we position the Company for future growth." Mr. Hull continued, "On behalf of the InMed team, I want to express our gratitude to Bryan for his significant contributions as a Director and Audit Chair over the past several years and we wish him all the best in his future endeavours."
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1. of the Annual Report for the period ended June 30, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270677
FAQ
Who is John Bathery and why did InMed (INM) appoint him to the board on October 16, 2025?
What experience does John Bathery bring to InMed (INM) related to business development?
How will John Bathery’s appointment affect InMed’s INM-901 and INM-089 programs?
When will Bryan Baldasare leave the InMed (INM) board?
Does John Bathery’s appointment signal upcoming partnership activity at InMed (INM)?
Is John Bathery’s board appointment effective immediately for InMed (INM)?
